Phase III trials show 99% SVR in types 1,2,4,5,6 after 12 week treatment, and 95% for type 3 after 8 week treatment. These trials used no NS5B inhibitor. Imagine it in combo with Sofosbuvir.

http://finance.yahoo.com/news/abbvie-abbv-presents-positive-data-152503586.html

Why they keep doing 8 week trials, especially for type 3 patients, baffles me. These drugs’ exorbitant prices do not come from their manufacturing cost … therefore, drop the price by 1/3 and sell 50% more product, get the same revenue and stop screwing around with people’s lives.

AbbVie on ENDURANCE-3:
https://news.abbvie.com/news/eight-weeks-treatment-with-abbvies-investigational-pan-genotypic-regimen-glecaprevirpibrentasvir-gp-achieved-high-svr12-rates-in-challenging-to-treat-genotype-3-chronic-hepatitis-c.htm

AbbVie on EXPEDITION-1:
https://news.abbvie.com/news/abbvies-investigational-pan-genotypic-ribavirin-free-regimen-glecaprevirpibrentasvir-gp-achieved-99-percent-svr12-rate-in-chronic-hepatitis-c-patients-with-compensated-cirrhosis.htm